Anti-Clotting Effect of Aspirin Wanes Over Time
Posted on 2004-03-26 03:56:00 in
Cardio-Vascular |
NEW YORK (Reuters Health) - Aspirin is widely used to prevent platelets in the blood clumping together and forming clots, but physicians in Rome report that aspirin's anti-platelet action declines with prolonged treatment.
However, this is not seen with another anti-clotting drug called ticlopidine, also known as Ticlid.
Previous research has suggested a progressive decrease in aspirin's clinical efficacy after two years of treatment, Dr. Fabio M. Pulcinelli and his associates explain in the Journal of the American College of Cardiology. To investigate further, the research team at the University "La Sapienza" monitored blood samples from 150 patients for two years after they started anti-platelet treatment.
In the lab, the maximal percentage of platelets that could be made to clump together decreased from 88 percent at the start of the study to 38 percent after two months. Thereafter, clumping increased progressively to 46 percent at 6 months, 48 percent at 12 months and 62 percent at 24 months.
In contrast, in a group of 80 similar patients, the anti-platelet effects of ticlopidine did not change significantly during two years of treatment.
The authors point out that other researchers have observed a reduction in cardiovascular events when treatment with aspirin was combined with clopidogrel, another anti-platelet agent.
"Future studies should therefore address the question of whether the superiority of such a combination is dependent on a more complete and efficient inhibition of platelet aggregation or on a protective effect provided by clopidogrel in patients with a progressively reduced sensitivity to aspirin," Pulcinelli's team concludes.
SOURCE: Journal of the American College of Cardiology, March 17, 2004.
However, this is not seen with another anti-clotting drug called ticlopidine, also known as Ticlid.
Previous research has suggested a progressive decrease in aspirin's clinical efficacy after two years of treatment, Dr. Fabio M. Pulcinelli and his associates explain in the Journal of the American College of Cardiology. To investigate further, the research team at the University "La Sapienza" monitored blood samples from 150 patients for two years after they started anti-platelet treatment.
In the lab, the maximal percentage of platelets that could be made to clump together decreased from 88 percent at the start of the study to 38 percent after two months. Thereafter, clumping increased progressively to 46 percent at 6 months, 48 percent at 12 months and 62 percent at 24 months.
In contrast, in a group of 80 similar patients, the anti-platelet effects of ticlopidine did not change significantly during two years of treatment.
The authors point out that other researchers have observed a reduction in cardiovascular events when treatment with aspirin was combined with clopidogrel, another anti-platelet agent.
"Future studies should therefore address the question of whether the superiority of such a combination is dependent on a more complete and efficient inhibition of platelet aggregation or on a protective effect provided by clopidogrel in patients with a progressively reduced sensitivity to aspirin," Pulcinelli's team concludes.
SOURCE: Journal of the American College of Cardiology, March 17, 2004.
Health Headlines
In a lab animal model, booming gut flora spawned by the Western diet is linked to obesity.
International study reaffirms importance of resolving the income gap between the richest and poorest people in developed countries.
Switzerland-based research team assesses the metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress hormones.
UCLA researchers find disability rates in Americans entering their 60s are on the rise, potentially fueled by the overweight/obesity epidemic.
Genetic clues to longevity discovered among a homogenous ethnic population.
Rush Alzheimer's Disease Center (USA) researchers find that a loss of muscle strength raises risk of Alzheimer’s Disease and mild cognitive impairment.
Stroke risk may rise in those with common infectious pathogens such as Chlamydia pneumoniae, Helicobacter pylori, and herpes simplex viruses.
First study in humans links bisphenol A (BPA) exposure to male sexual function problems.
Simple steps in the community can promote walking among residents.
Study finds that people who are dissatisfied with their workplace bosses not only take more sick leave, but are at increased risk of suffering a heart attack.
upcoming Events
U.S. Events
congresses
fellowships
-
Aesthetic Medicine Module I
Las Vegas, NV | Dec. 9-10, 2009 -
Anti-Aging & Regenerative Medicine Modules I, II, III & IX
Las Vegas, NV | Dec. 10-12, 2009 -
Preventative Medicine, Nutrition & Sports Medicine Module I
Las Vegas, NV | Dec. 9-11, 2009 -
Fellowship in Preventative Medicine, Nutrition & Sports Medicine Module III
Las Vegas, NV | Dec. 11-12, 2009
symposium
-
Advanced Hormone Symposium
Chicago, IL | Oct. 8-10, 2010
VIDEO: Brain Age Workshop
Dr. Eric Braverman, Director of The Place for Achieving Total Health
(PATH Medical), Chairs the
Brain Age Workshop taking place Dec. 9, 2009.
Held in conjunction with the Winter Session of the 17th Annual World
Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies.
The Brain Age Workshop features presentations on Brain Mind Assessment
via Neuropsychological Analysis, Movement Deficiency Syndrome,
Hormones and the Brain, Nootropic Drug Mechanisms, and Traumatic Brain
Injury. View this video to learn about Dr. Braverman’s brain-based
model of aging and age modulation.
International Events
- Mexico City | Jan. 15-17, 2010
- Milan | Mar. 18-20, 2010
- Kuala Lumpur | Apr. 29 - May 2, 2010
- Jakarta | May 2010 (pending)
- Bucharest | May 2010 (pending)
- Seoul | May 2010 (pending)
- Melbourne | Aug. 21-22, 2010
- Dubai | Oct. 26-27, 2010
- Bali | October 2010 (pending)
- Mainz-Frankfurt | Nov. 8-10, 2010
- Sao Paulo | Nov. 12-14, 2010
- Shanghai | November 2010 (pending)
